Wave’s bullish start to the week was driven by the encouraging readout of a Phase 1 clinical study of WVE-007, its obesity drug candidate. Weight-loss drugs are all the rage these days in the U.S., …
Why Wave Life Sciences Stock Crushed it Again Today
view original post